KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Liabilities and Shareholders Equity (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $446.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 9.13% year-over-year to $446.4 million, compared with a TTM value of $926.5 million through Dec 2025, down 51.8%, and an annual FY2024 reading of $490.4 million, down 5.13% over the prior year.
  • Liabilities and Shareholders Equity was $446.4 million for Q3 2025 at Biocryst Pharmaceuticals, down from $480.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $529.9 million in Q2 2023 and bottomed at $446.4 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 3 years is $492.8 million, with a median of $490.8 million recorded in 2024.
  • The sharpest move saw Liabilities and Shareholders Equity decreased 10.84% in 2024, then rose 2.6% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $517.0 million in 2023, then decreased by 5.13% to $490.4 million in 2024, then fell by 8.97% to $446.4 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for BCRX at $446.4 million in Q3 2025, $480.0 million in Q1 2025, and $490.4 million in Q4 2024.